Skip to content
‹ Back to IndustriesHealthcare

CurveBeam Connect: It’s Time to Find a New Gold Standard for Orthopedic Imaging

CurveBeam, the internationally recognized leader in Extremity CT imaging, is excited to share their new podcast CurveBeam Connect, a show where anyone interested in healthcare and technology can learn about the amazing new innovations that are affecting medicine. Our host is Vinti Singh, Director of Marketing at CurveBeam, and today’s guest is Dr. Francois…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from CurveBeam AI on MarketScale.

Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI in a free MarketScale workspace. Qualifying companies also get one professional video edit a month. No credit card.

Try it Free

CurveBeam, the internationally recognized leader in Extremity CT imaging, is excited to share their new podcast CurveBeam Connect, a show where anyone interested in healthcare and technology can learn about the amazing new innovations that are affecting medicine.

Our host is Vinti Singh, Director of Marketing at CurveBeam, and today’s guest is Dr. Francois Lintz, M.D., Orthopedic Surgeon at Clinique de L’Union in Toulouse, France. Dr. Lintz is a renowned foot & ankle surgeon, as well as: Scientific Committee Chair for the French Foot and Ankle Society, the Fellowship Committee Chair for the European Foot Society, and a Founder and Member of the International Weight-Bearing CT Society.

Dr. Lintz has been using a CurveBeam Weight-Bearing CT System since 2016 in both his daily practice and his research, and has found they’re more accurate than the X-ray, which project images and represent a 3D structure in a 2-dimensional format.

“It’s not reality itself,” said Dr. Lintz. “When we plan surgeries– we’d like to know exactly what we’re looking at. In film, it’s distorted by a number of effects and makes it more difficult for us in terms of angles, distances, and things we require to plan for a good surgery.”

Conventional methods, like X-rays, are thought of as the “gold standard,” but there has been a huge emergence of three-dimensional imaging in other fields and industries. The weight-bearing tool is a game changer, giving the ability to see the foot and ankle in 3D, in a standing position. We can see actual damage with a model that very accurately represents reality.

In this podcast, the two will talk about CurveBeam systems, the InstaX plugins, all the different views that are available, and how these views are available at the click of a button, without an X-Ray tech moving the patient and tube around.

For the latest news, videos, and podcasts in the Healthcare Industry, be sure to subscribe to our industry publication.

Follow us on social media for the latest updates in B2B!

Twitter – @HealthMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

CurveBeam AI

Part of this channel

CurveBeam AI

AI-powered 3D bone analysis for orthopedic surgical planning.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0. No credit card. Company confirmation required.

More Healthcare Insights

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Medicare will pay up to $137.53 per case in 2027 for BriefCase‑Triage

Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage. Holland & Knight said hospitals will be eligible for NTAP reimbursement for use of Aidoc’s CARE Body CT Multi-Triage beginning Oct. 1, 2026, with supplemental payments continuing for three years.

  • 01Radiology Business reported Medicare will pay a maximum of $137.53 per case in 2027 for BriefCase-Triage.
  • 02Holland & Knight said CMS approved an NTAP designation for Aidoc’s CARE Body CT Multi-Triage, with hospitals eligible for NTAP reimbursement beginning Oct. 1, 2026, with supplemental payments continuing for three years.

Sep 23, 2026

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raises CAD $4.24M to expand its LLM-guided specialty care workflows

Blair Health raised CAD $4.24 million in a pre-seed round, according to Fierce Healthcare. It plans to expand protocol-driven virtual specialty care across Canada and the U.S.

  • 01Blair Health raised CAD $4.24 million in pre-seed funding.
  • 02Qualified Health positions its AI platform around safety and governance, including clinician oversight, auditability and traceability, according to Fierce Healthcare.

Sep 23, 2026

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512